Interferon gamma-1b

Summary

Interferon gamma-1b (IFN-γ1b) is a recombinant human interferon-gamma produced in E. coli, approved for reducing the frequency and severity of serious infections in chronic granulomatous disease (CGD) and delaying disease progression in severe malignant osteopetrosis. It is a potent immunomodulatory cytokine with broad effects on innate and adaptive immunity.

Mechanism of Action

Binds to the interferon-gamma receptor (IFNGR1/IFNGR2) complex on cell surfaces, activating the JAK-STAT signaling pathway (JAK1/JAK2 and STAT1), leading to transcription of interferon-stimulated genes. Enhances macrophage activation, promotes Th1 immune responses, upregulates MHC class I and II expression, and augments oxidative burst in phagocytes, thereby improving killing of intracellular pathogens and tumor cells.

Routes of Administration

Goals & Uses

• Reduction of serious infections in chronic granulomatous diseaseImmunodeficiency / Infection ProphylaxisHigh
• Antiviral / antitumor immunotherapyOncology / AntiviralLow
• Treatment of idiopathic pulmonary fibrosisFibrosis / Pulmonary DiseaseLow
• Delay of disease progression in severe malignant osteopetrosisBone Disease / ImmunomodulationModerate

Contraindications

• Pre-existing severe neurological or seizure disordersNeurologicalModerate
• Severe hepatic impairmentOrganModerateLiver function concerns
• Pre-existing severe cardiac diseaseCardiovascularModerate
• Hypersensitivity to interferon-gamma or E. coli-derived proteinsAllergy / ImmunologyHigh

Adverse Effects

• Elevated liver enzymes (AST/ALT)HepatotoxicityUncommon
• Injection site reactionsLocalCommon
• Central nervous system effects (decreased mental status, gait disturbance, dizziness)NeurologicalUncommon
• Neutropenia / thrombocytopeniaHematologicUncommon
• Flu-like symptoms (fever, chills, myalgia, headache, fatigue)Systemic / ConstitutionalCommon
• Cardiovascular effects (hypotension, tachycardia, syncope)CardiovascularRare

Drug Interactions

• Zidovudine (AZT)Moderate
• CYP450-metabolized drugs (e.g., theophylline, warfarin, phenytoin)Moderate
• Immunosuppressants (e.g., corticosteroids, cyclosporine)Moderate
• Myelosuppressive agents (e.g., azathioprine, cyclophosphamide)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• LactationReproductiveRelative
• Patients with pre-existing autoimmune diseaseAutoimmuneRelative
• Pediatric patients < 0.5 m² BSAPediatricRelative
• Elderly patientsAgeRelative

Regulatory Status

• European UnionApprovedApproved: Chronic granulomatous diseaseApproved by EMA for CGD; regulatory history includes various national approvals across member states.
• United StatesApprovedApproved: Chronic granulomatous disease (CGD) – reducing frequency and severity of serious infections, Severe malignant osteopetrosis – delaying disease progressionApproved by FDA; marketed as Actimmune. Orphan drug designation for both indications. Not approved for IPF.
• United KingdomApprovedApproved: Chronic granulomatous diseaseApproved for CGD; available through specialist prescription.

FDA-approved (Actimmune) for CGD and severe malignant osteopetrosis. Not approved for idiopathic pulmonary fibrosis despite prior trials. Orphan drug designation for CGD and osteopetrosis.

Evidence & Sources

No sources recorded yet.